S100 Calcium-Binding Protein B

S100B belongs to the S100 family of low-molecular-weight proteins characterized by two calcium-binding domains. In the brain, S100B is expressed at high concentrations in astrocytes, where it participates in calcium homeostasis, cell growth regulation, and intracellular signaling. At physiological (nanomolar) concentrations, S100B exerts neurotrophic effects — promoting neuronal survival and neurite extension. However, at higher (micromolar) concentrations, such as those released during brain injury, S100B can activate inflammatory pathways and contribute to neurotoxicity through the receptor for advanced glycation end products (RAGE).

When the blood-brain barrier is disrupted — whether by trauma, ischemia, or infection — S100B crosses into the peripheral circulation, where it becomes detectable by immunoassay. S100B has a relatively short half-life of approximately 25 minutes in serum, meaning that it rises quickly after brain injury and clears rapidly once the source of release is resolved. This rapid kinetic profile makes S100B useful as an early indicator but limits its detection window for delayed presentations. Serum S100B levels above 0.10 µg/L are generally considered elevated and associated with an increased probability of intracranial pathology following head trauma.

A notable limitation of S100B as a brain injury biomarker is its expression in extracerebral tissues. Adipocytes, chondrocytes, and melanocytes all produce S100B, which means that polytrauma patients with bone fractures, soft tissue injury, or even melanoma may show elevated S100B levels without significant brain injury. This limited specificity for neurological pathology has driven the development of more brain-specific alternatives such as GFAP, though S100B remains incorporated into clinical decision rules for mild head injury in Scandinavian and some European guidelines.

Prevena Health is investigating whether continuous S100B monitoring, as part of a multi-biomarker neurological panel, may support earlier identification of blood-brain barrier disruption and brain injury events. While S100B has limitations in specificity when used alone, its rapid kinetic profile and well-established clinical reference ranges make it a valuable component in combination with more brain-specific markers like GFAP and UCH-L1.

Continuous surveillance may help address one of S100B's key limitations: its short detection window. By monitoring S100B levels in real time through a wearable platform, transient elevations that would be missed by delayed blood draws may be captured, potentially providing a more complete picture of blood-brain barrier integrity over time. This approach may support research in perioperative neurology, sports concussion monitoring, and longitudinal assessment of neurological risk in high-exposure populations.